PML and neoplasm: Studies reported that knocking out TRIB3 inhibited tumor formation and cancer progression, disrupting TRIB3–SQSTM1 or TRIB3–PML/RARα interactions through specific peptides, which is a potential strategy for treatment of certain solid cancers and acute promyelocytic leukemia [19–21].